4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
NewcelX Ltd. (NCEL) operates in the Biotechnology industry and is headquartered in Kloten, Switzerland with about 9 employees. Its market capitalization is roughly $22 million. In the fiscal year ended 2025-12-31, NCEL reported $0M in revenue and ($8M) in net income.
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($2M) | ($2M) | ($3M) | ($6M) | — |
| Net Income | ($8M) | ($7M) | ($3M) | ($6M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $11M | $1M | $2M | $4M | — |
| Total Liabilities | $4M | $9M | $3M | $4M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NCEL viewer.
About TickerBase · Data methodology & sources